Going LIVE Today at 5pm: Our Special Event on India's Revival
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 5.8 |
No. of shares | m | 282.17 |
% ch week | % | 13.1 |
% ch 1-mth | % | 13.1 |
% ch 12-mth | % | 81.8 |
52 week H/L | Rs | 572.7/253.0 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 879 | 1,262 | 993 | 930 | 712 | |
Low | Rs | 752 | 672 | 729 | 517 | 484 | |
Sales per share (Unadj.) | Rs | 244.4 | 271.1 | 325.5 | 322.6 | 349.6 | |
Earnings per share (Unadj.) | Rs | 17.5 | 26.3 | 39.3 | 28.5 | 32.8 | |
Diluted earnings per share | Rs | 16.8 | 26.3 | 39.3 | 28.5 | 32.8 | |
Cash flow per share (Unadj.) | Rs | 27.1 | 34.6 | 48.7 | 39.2 | 44.3 | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
Adj. dividends per share | Rs | 1.92 | 2.00 | 2.00 | 2.00 | 2.00 | |
Dividend yield (eoy) | % | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | |
Book value per share (Unadj.) | Rs | 86.1 | 128.6 | 159.2 | 183.0 | 198.6 | |
Adj. book value per share | Rs | 82.8 | 128.6 | 159.2 | 183.0 | 198.6 | |
Shares outstanding (eoy) | m | 271.29 | 282.16 | 282.17 | 282.17 | 282.17 | |
Bonus/Rights/Conversions | - | - | ESOP | - | - | ||
Price / Sales ratio | x | 3.3 | 3.6 | 2.6 | 2.2 | 1.7 | |
Avg P/E ratio | x | 46.6 | 36.7 | 21.9 | 25.4 | 18.2 | |
P/CF ratio (eoy) | x | 30.1 | 27.9 | 17.7 | 18.5 | 13.5 | |
Price / Book Value ratio | x | 9.5 | 7.5 | 5.4 | 4.0 | 3.0 | |
Dividend payout | % | 11.4 | 7.6 | 5.1 | 7.0 | 6.1 | |
Avg Mkt Cap | Rs m | 221,284 | 272,778 | 242,991 | 204,206 | 168,625 | |
No. of employees | `000 | 9.5 | 10.0 | 13.0 | 13.7 | 12.0 | |
Total wages/salary | Rs m | 12,024 | 13,782 | 16,408 | 18,718 | 20,561 | |
Avg. sales/employee | Rs Th | 6,961.1 | 7,630.5 | 7,083.9 | 6,636.8 | 8,196.0 | |
Avg. wages/employee | Rs Th | 1,262.5 | 1,374.8 | 1,265.4 | 1,364.7 | 1,708.1 | |
Avg. net profit/employee | Rs Th | 499.0 | 741.2 | 855.1 | 586.1 | 768.5 |
GLENMARK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 66,298 | 76,496 | 91,857 | 91,031 | 98,655 | |
Other income | Rs m | 219 | 200 | 374 | 914 | 2,081 | |
Total revenues | Rs m | 66,516 | 76,696 | 92,230 | 91,945 | 100,736 | |
Gross profit | Rs m | 10,225 | 14,372 | 20,367 | 16,154 | 15,858 | |
Depreciation | Rs m | 2,600 | 2,343 | 2,644 | 3,019 | 3,259 | |
Interest | Rs m | 1,902 | 1,789 | 2,373 | 2,856 | 3,346 | |
Profit before tax | Rs m | 5,943 | 10,440 | 15,724 | 11,193 | 11,335 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | -810 | 0 | 1,672 | |
Tax | Rs m | 1,190 | 3,009 | 3,827 | 3,155 | 3,756 | |
Profit after tax | Rs m | 4,752 | 7,430 | 11,088 | 8,039 | 9,250 | |
Gross profit margin | % | 15.4 | 18.8 | 22.2 | 17.7 | 16.1 | |
Effective tax rate | % | 20.0 | 28.8 | 24.3 | 28.2 | 33.1 | |
Net profit margin | % | 7.2 | 9.7 | 12.1 | 8.8 | 9.4 |
GLENMARK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 53,199 | 59,043 | 68,746 | 69,887 | 66,968 | |
Current liabilities | Rs m | 37,111 | 39,993 | 27,027 | 32,879 | 40,211 | |
Net working cap to sales | % | 24.3 | 24.9 | 45.4 | 40.7 | 27.1 | |
Current ratio | x | 1.4 | 1.5 | 2.5 | 2.1 | 1.7 | |
Inventory Days | Days | 70 | 75 | 85 | 81 | 83 | |
Debtors Days | Days | 138 | 119 | 96 | 93 | 81 | |
Net fixed assets | Rs m | 17,445 | 21,416 | 24,132 | 28,892 | 33,322 | |
Share capital | Rs m | 271 | 282 | 282 | 282 | 282 | |
"Free" reserves | Rs m | 23,086 | 36,014 | 44,643 | 51,353 | 55,770 | |
Net worth | Rs m | 23,357 | 36,296 | 44,925 | 51,635 | 56,052 | |
Long term debt | Rs m | 25,744 | 24,873 | 45,363 | 41,418 | 35,738 | |
Total assets | Rs m | 87,429 | 101,929 | 117,639 | 125,954 | 132,888 | |
Interest coverage | x | 4.1 | 6.8 | 7.6 | 4.9 | 4.4 | |
Debt to equity ratio | x | 1.1 | 0.7 | 1.0 | 0.8 | 0.6 | |
Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | |
Return on assets | % | 7.6 | 9.0 | 11.4 | 8.6 | 9.5 | |
Return on equity | % | 20.3 | 20.5 | 24.7 | 15.6 | 16.5 | |
Return on capital | % | 16.0 | 20.0 | 19.1 | 15.1 | 17.8 | |
Exports to sales | % | 44.8 | 43.2 | 0 | 0 | 0 | |
Imports to sales | % | 7.1 | 7.4 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 29,720 | 33,044 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 4,680 | 5,672 | 0 | 0 | 0 | |
Fx inflow | Rs m | 31,299 | 36,945 | 56,152 | 36,317 | 62,998 | |
Fx outflow | Rs m | 10,856 | 61,066 | 8,084 | 9,720 | 22,859 | |
Net fx | Rs m | 20,443 | -24,122 | 48,068 | 26,598 | 40,140 |
GLENMARK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 4,817 | 3,449 | 6,574 | 16,481 | 13,242 | |
From Investments | Rs m | -5,400 | -8,802 | -7,124 | -10,133 | -6,990 | |
From Financial Activity | Rs m | 1,992 | 6,986 | 5,432 | -4,685 | -7,387 | |
Net Cashflow | Rs m | -311 | 934 | 1,992 | 1,770 | -2,971 |
Share Holding
|
Company Information
|
CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.4 |
Read: GLENMARK PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: AMAR REMEDIES AJANTA PHARMA STRIDES PHARMA SCIENCE CIPLA ALEMBIC
Compare GLENMARK PHARMA With: AMAR REMEDIES AJANTA PHARMA STRIDES PHARMA SCIENCE CIPLA ALEMBIC
Compare GLENMARK PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 304 points, down 0.6% at 48,240 levels.
GLENMARK PHARMA share price is trading up by 5% and its current market price is Rs 540. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is GLENMARK PHARMA (up 5.2%). The top losers are JUBILANT PHARMOVA (down 0.2%) and GSK PHARMA (down 0.3%).
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More